Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
企業コードXCUR
会社名Exicure Inc
上場日May 09, 2018
最高経営責任者「CEO」Mr. Paul Kang
従業員数7
証券種類Ordinary Share
決算期末May 09
本社所在地2430 N. Halsted St.
都市CHICAGO
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号60614
電話番号18476731707
ウェブサイトhttps://www.exicuretx.com/
企業コードXCUR
上場日May 09, 2018
最高経営責任者「CEO」Mr. Paul Kang
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし